BioNexus Gene Lab (BGLC) Competitors $6.31 -0.51 (-7.49%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$6.33 +0.02 (+0.32%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock BGLC vs. ENZ, BRTX, MGRX, SSY, OTRK, ACON, DHAC, ATIP, VSEE, and NIVFShould you be buying BioNexus Gene Lab stock or one of its competitors? The main competitors of BioNexus Gene Lab include Enzo Biochem (ENZ), Biorestorative Therapies (BRTX), Mangoceuticals (MGRX), SunLink Health Systems (SSY), Ontrak (OTRK), Aclarion (ACON), Digital Health Acquisition (DHAC), ATI Physical Therapy (ATIP), VSee Health (VSEE), and NewGenIvf Group (NIVF). These companies are all part of the "healthcare" industry. BioNexus Gene Lab vs. Its Competitors Enzo Biochem Biorestorative Therapies Mangoceuticals SunLink Health Systems Ontrak Aclarion Digital Health Acquisition ATI Physical Therapy VSee Health NewGenIvf Group BioNexus Gene Lab (NASDAQ:BGLC) and Enzo Biochem (NYSE:ENZ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends. Is BGLC or ENZ more profitable? BioNexus Gene Lab has a net margin of -22.85% compared to Enzo Biochem's net margin of -75.34%. Enzo Biochem's return on equity of -7.96% beat BioNexus Gene Lab's return on equity.Company Net Margins Return on Equity Return on Assets BioNexus Gene Lab-22.85% -24.18% -20.14% Enzo Biochem -75.34%-7.96%-5.49% Do institutionals and insiders believe in BGLC or ENZ? 18.9% of BioNexus Gene Lab shares are owned by institutional investors. Comparatively, 36.9% of Enzo Biochem shares are owned by institutional investors. 0.7% of BioNexus Gene Lab shares are owned by insiders. Comparatively, 11.4% of Enzo Biochem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has higher earnings & valuation, BGLC or ENZ? BioNexus Gene Lab has higher earnings, but lower revenue than Enzo Biochem. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioNexus Gene Lab$9.51M1.19-$1.60MN/AN/AEnzo Biochem$29.09M0.59-$26.08MN/AN/A Which has more risk and volatility, BGLC or ENZ? BioNexus Gene Lab has a beta of 5.08, indicating that its share price is 408% more volatile than the S&P 500. Comparatively, Enzo Biochem has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Does the media prefer BGLC or ENZ? In the previous week, BioNexus Gene Lab had 7 more articles in the media than Enzo Biochem. MarketBeat recorded 7 mentions for BioNexus Gene Lab and 0 mentions for Enzo Biochem. BioNexus Gene Lab's average media sentiment score of 0.00 equaled Enzo Biochem'saverage media sentiment score. Company Overall Sentiment BioNexus Gene Lab Neutral Enzo Biochem Neutral SummaryBioNexus Gene Lab and Enzo Biochem tied by winning 5 of the 10 factors compared between the two stocks. Get BioNexus Gene Lab News Delivered to You Automatically Sign up to receive the latest news and ratings for BGLC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BGLC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BGLC vs. The Competition Export to ExcelMetricBioNexus Gene LabMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.55M$7.31B$5.54B$9.05BDividend YieldN/A2.78%5.24%4.02%P/E RatioN/A27.9427.4320.22Price / Sales1.1932.39416.87118.64Price / CashN/A22.0136.8958.07Price / Book1.366.698.035.67Net Income-$1.60M$233.06M$3.18B$249.13M7 Day Performance127.76%3.33%2.88%3.28%1 Month Performance95.93%3.72%3.69%5.56%1 Year Performance36.00%37.40%36.02%21.12% BioNexus Gene Lab Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BGLCBioNexus Gene Lab0.4326 of 5 stars$6.31-7.5%N/A+33.5%$11.55M$9.51M0.0030Gap DownENZEnzo BiochemN/A$0.33-14.8%N/A-69.6%$17.03M$29.09M0.00520Gap DownHigh Trading VolumeBRTXBiorestorative Therapies2.7696 of 5 stars$1.71+4.0%$18.00+955.7%-15.3%$12.79M$400K-1.167MGRXMangoceuticals0.8611 of 5 stars$2.03+8.9%N/A-97.8%$10.47M$620K-0.443News CoverageSSYSunLink Health SystemsN/A$0.92-5.0%N/A+16.6%$6.49M$31.09M6.591,376Positive NewsOTRKOntrak2.9011 of 5 stars$1.06-20.7%$45.00+4,165.4%-83.8%$4.45M$10.85M-0.07250News CoverageACONAclarion2.5084 of 5 stars$6.97-2.0%$11,758.50+168,722.7%-99.7%$4.04M$50K0.007News CoverageDHACDigital Health AcquisitionN/A$1.12+2.8%N/A-88.6%$4.04MN/A0.002,021Gap UpHigh Trading VolumeATIPATI Physical Therapy0.1968 of 5 stars$0.88-12.9%N/A-80.8%$3.88M$741.86M-0.055,600Gap DownVSEEVSee Health1.2371 of 5 stars$1.07-4.5%$5.00+367.3%N/A$3.86M$6.38M0.00N/ANIVFNewGenIvf GroupN/A$1.09-0.4%N/A-99.5%$576K$5.43M0.00N/APositive NewsGap Up Related Companies and Tools Related Companies ENZ Alternatives BRTX Alternatives MGRX Alternatives SSY Alternatives OTRK Alternatives ACON Alternatives DHAC Alternatives ATIP Alternatives VSEE Alternatives NIVF Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BGLC) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNexus Gene Lab Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNexus Gene Lab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
